GLP1R and type 2 diabetes mellitus: The glucagon‐like peptide‐1 (GLP‐1) receptor is a well‐established pharmacological target for the treatment of both type 2 diabetes and obesity due to its beneficial effects on weight loss and pancreatic beta cell function (Andersen, Lund, Knop, & Vilsbøll, 2018).